Table 1_The impact of public participatory environmental regulation on carbon emission intensity: a policy text analysis.docx by Jianzu Wu (13935369)

“…The findings reveal that: (1) public participatory environmental regulation significantly reduces carbon emission intensity; specifically, baseline regression results indicate that a one-unit increase in public participatory environmental regulation intensity leads to a 0.05 unit decrease in carbon emission intensity, significant at the 1% level; (2) mediation analysis demonstrates that public environmental participation serves as a significant intermediary between environmental regulation and carbon emission reduction; (3) heterogeneity analysis indicates that official characteristics significantly moderate policy effectiveness, with regulations implemented by non-local, shorter-tenured, and less-educated officials showing stronger inhibitory effects on carbon emissions compared to their counterparts. …”

DataSheet2_Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.docx by Jung Hoon Cha (19723588)

“…</p>Conclusions<p>Our study underscores the pivotal role of CHIT1 in MASH. The observed significant improvement in inflammation and hepatic fibrosis, particularly at higher doses of the CHIT1 inhibitor, strongly suggests the potential of CHIT1 as a therapeutic target in MASH accompanied by progressive liver fibrosis.…”

DataSheet1_Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.zip by Jung Hoon Cha (19723588)

“…</p>Conclusions<p>Our study underscores the pivotal role of CHIT1 in MASH. The observed significant improvement in inflammation and hepatic fibrosis, particularly at higher doses of the CHIT1 inhibitor, strongly suggests the potential of CHIT1 as a therapeutic target in MASH accompanied by progressive liver fibrosis.…”

The Patient Global Impression of Change as a complementary tool to account for neurobehavioral and mental health symptom improvement for patients with concussion by Rosemay A. Remigio-Baker (7864583)

“…</p> <p>Higher PGIC scores were related to a higher prevalence of clinically-relevant <i>decrease</i> in NSI, PCL-5 or PHQ-8 scores. …”

<i>IRF1</i> impacts VACV replication in glucose/IFN-γ primed but not galactose conditions. by Tyron Chang (9922533)

Ingenuity pathway analysis of tonic ISG subclasses. by Tyron Chang (9922533)

Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers by Mandeep K. Marway (21734690)

“…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …”

Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers by Mandeep K. Marway (21734690)

“…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …”

Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers by Mandeep K. Marway (21734690)

“…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …”

RBM39 methylation by PRMT6 increases RBM39 stability by inhibiting its ubiquitination. by Tongjia Zhang (16496661)

Analysis of host and interferon-induced responses in glucose/galactose infected with vaccinia virus. by Tyron Chang (9922533)

Vaccinia virus and VSV infections of <i>STAT1</i> and <i>IRF1</i> KO cells grown in glucose/galactose with and without IFN-γ priming. by Tyron Chang (9922533)

Glucose but not galactose culturing of IFN-γ primed cells reduces VACV and HSV-1 replication. by Tyron Chang (9922533)

Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

“…Lower income levels are associated with decreased survival, potentially due to delays in diagnosis or treatment and a higher probability of advanced staging at diagnosis, These inequities persist even among relatively advantaged populations, such as formal employee who are assumed to have fewer barriers to accessing healthcare services compared to informal workers.…”

Glucose/galactose selectively alters ISG protein not RNA levels in interferon-primed cells. by Tyron Chang (9922533)

Data Sheet 1_Factors associated with cognitive flexibility in people with opioid-use disorder: a pilot study.docx by Paul S. Regier (8277792)

“…Impulsiveness, social function, and depressive symptoms were highly inter-related; however, only higher impulsiveness (r = -.48, p = 0.006) and more social impairment (r = -.47, p = 0.007) significantly correlated with decreased CET (but not n-Back) performance. …”

LLL12B, APTO-253, and VK-1727 inhibit cell growth and induce apoptosis in LCL. by Huanzhou Xu (8129922)

Table 1_Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis.docx by Dongsheng Wu (2469307)

“…</p>Results<p>The randomized controlled trials (RCTs) included in this review examined dietary supplementation with eight polyphenols—curcumin, resveratrol, anthocyanins, quercetin, salidroside, dietary beetroot juice, pomegranate juice, and adjunctive oral AKL1 treatment—across a total of 894 participants. This systematic review and meta-analysis revealed that, compared to a placebo; ① Curcumin significantly reduced systolic blood pressure (SBP) and improved FEV1(SMD=-0.82, 95%CI -1.53 to -0.11); ② Salidroside was effective in reducing thrombotic markers (TT, D-D), inflammatory factors (TNF-α) and symptom scores (CAT) (p<0.01); ③ Resveratrol significantly downregulates serum TNF-α and IL-8 levels (p=0.003); ④ Anthocyanins may accelerate lung function decline (decreased FEV1/FVC, which needs to be interpreted with caution); ⑤ Other polyphenols (quercetin, pomegranate juice, AKL1, etc.) did not show significant efficacy or insufficient evidence. …”

Table 1_The efficacy of infliximab combined with partial enteral nutrition in the treatment of Crohn’s disease: a cohort study.docx by Chen Huang (202847)

“…</p>Results<p>Among the 176 included patients, 99 (56%) were in the IFX monotherapy group, and 77 (44%) were in the IFX + PEN group. A significantly higher proportion of patients in the IFX + PEN group achieved clinical response (defined as a CDAI decrease ≥70 points) compared to those in the IFX group at 14 weeks (87.01% vs. 74.75%, p = 0.043), as well as a higher proportion achieving endoscopic remission at 54 weeks (84.42% vs. 65.66%, p = 0.005). …”

Study design and plasma viral load. by Zoey K. Wallis (17725175)